The pace of innovation is accelerating as medical IT providers look to integrate artificial intelligence into their services for provider operations, medical testing, patient engagement, and other services. other use cases.
Aspira Women’s Health, Belong.life and Outbound AI are just three companies that have announced new AI-based technologies that support cutting-edge discovery in ovarian cancer, with corresponding cancer patient engagement and payment management..
AI virtual agent for payment
Seattle-based Outbound AI, founded in 2021, announced Tuesday that it has expanded its cloud-based PayerVA Dashboard with generalized AI that “enhances human talent.” while reducing the burden on the payment specialist.
The company says its mission is to remove the burden of administrative work in the healthcare revenue cycle and create tools that help reduce administrative costs, improve productivity, and enhance the “experience.” Daily work”.
“The amount of time medical billing teams spend on the phone with payers is truly astounding,” said Stead Burwell, founder and CEO of Outbound AI.
“It can easily take up two-thirds of their day,” he said. This is not only counterproductive, but also reduces job satisfaction and performance.
According to Outbound AI, PayerVA’s virtual agents navigate payer’s interactive voice response systems, waiting and talking to human representatives. They take “comprehensive notes” and, by leveraging GPT, generate call summaries and narrative transactions.
“Our AI virtual agents are specially trained to handle common phone-based tasks so talent can become more strategic and get more done,” said Burwell.
As Jonathan Wiggs, co-founder and CTO of the incubated startup at Madrona Venture Labs, explains, generic AI agents simulate how experienced payments team members create stories and follow the same standards.
“We’re not just leveraging the capabilities of GPT, we’re doing so in a highly secure, HIPAA-compliant way through Microsoft Azure,” he added.
“This is important for any company serving the healthcare industry, especially considering the business association agreement required under HIPAA is not available if using GPT directly through OpenAI.”
Since the launch of the claims platform, a host of new capabilities, including denial management and pre-authorization, have been added.
miRNA-based cancer diagnosis
Ovarian cancer is highly lethal in part because of how difficult it has historically been to diagnose.
Aspira Women’s Health has signed an exclusive licensing agreement with Boston-based Dana-Farber Cancer Institute to design and develop a non-invasive miRNA-based test that will use circulating microRNAs – alone or in combination with proteins or other factors – to identify ovarian cancer in women with adnexal tumours.
“The addition of this new non-invasive, molecular-based risk assessment tool to our portfolio will be another important step forward in providing information to physicians to determine the pathogenesis of the disease.” appropriate treatment,” Nicole Sandford, president and chief executive officer, said in a statement Thursday.
According to the company, the new test will be part of the company’s ovarian cancer risk assessment portfolio, which combines noninvasive blood-based tests for use in the initial clinical assessment of risk. ovarian cancer in women with benign or unspecified adnexal tumours with the use of FDA-approved products that detect risk of malignancy in the ovary scheduled for surgery.
Dipanjan Chowdhury, co-developer and head of Radiation and Genomic Stabilization at DFCI adds: “This technique could help address the significant unmet diagnostic need for ovarian cancer by non-invasive, easy, fast and affordable diagnostics.”
Customizable AI Cancer Advisor
According to Belong.Life, a provider of patient engagement and community platforms, Dave brings a new level of support to cancer patients and their families.
Eliran Malki, co-founder and CEO, said: “Dave, Belong’s AI oncology mentor, marks an important milestone in our journey to revolutionizing healthcare.”
“Dave delivers intelligent, personalized and instantly accessible information that can dramatically improve the quality of care and life for millions of patients worldwide.”
Dave is a large language model that also uses natural language processing trained on patient-doctor and patient-patient interaction data compiled from the Belong’s Beating Cancer Together app and tested by more than 10,000 cancer patients.
It can provide cancer-specific, comprehensive and empathetic answers to the challenges of cancer patients. According to the company, Dave also keeps a long-term memory of previous correspondence, allowing for continuous communication across multiple chat sessions.
It is freely available to users on the Belong’s Beating Cancer Together app and is also available as a customizable SaaS solution for hospitals, providers, and patient support programs. Providers may include internal clinical guidelines for optimal and exclusive use.
Andrea Fox is the senior editor of Healthcare IT News.
Email: [email protected]
Healthcare IT News is a publication of HIMSS Media.
